ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Diagnostic Value of Neutrophil CD64 Index in Diabetic Foot Osteomyelitis.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Managing Bone Infections Beyond Systemic Antibiotics: A Scoping Review.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to assess the value of the Neutrophil CD64 (nCD64) index as a novel, rapid biomarker for the diagnosis of Diabetic foot osteomyelitis (DFO), with the goal of enhancing the accuracy of early detection. Methods: A total of 142 hospitalized patients with type 2 diabetes complicated by diabetic foot infection were included. Participants were categorized into a Non-DFO group (84 cases) and a DFO group (58 cases) based on the presence or absence of osteomyelitis. The white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and the nCD64 index were compared between the two groups. Logistic regression analysis was performed to identify risk factors associated with DFO. Receiver operating characteristic (ROC) curves were generated, and the area under the curve (AUC) was calculated to evaluate the sensitivity and specificity of the nCD64 index in diagnosing DFO. Results: The nCD64 index was significantly elevated in the DFO group compared to the Non-DFO group (P<0.05). Logistic regression analysis indicated that the nCD64 index and ESR were independent risk factors for DFO (P < 0.05). The ROC-AUC analysis indicated that both the nCD64 index and ESR were associated with DFO. The nCD64 index exhibited superior predictive value compared to ESR (AUC: 0.895 vs 0.846). Specifically, the nCD64 index demonstrated the highest sensitivity at 96.6%, while ESR showed the highest specificity at 82.1%. When combined, the predictive value of the nCD64 index and ESR was optimal, with an AUC of 0.937, sensitivity of 86.2%, and specificity of 91.7%. Conclusion: The nCD64 index may serve as an effective new biomarker for the early detection of DFO. The combination of the nCD64 index and ESR could further enhance diagnostic accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.